PF-Atlas › Clinical Trials › NCT03946449
Study of Fazirsiran in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease
ARO-AAT · Phase 2
Registry ID
NCT03946449
Phase
Phase 2
Status
Completed
Drug / intervention
ARO-AAT
Sponsor
Arrowhead Pharmaceuticals
Start
2019-10-31
Enrollment
16
Locations
4
About this trial
The purpose of this study is to evaluate the the safety and efficacy of the investigational product, fazirsiran (TAK-999, ARO-AAT), administered subcutaneously to patients with alpha-1 antitrypsin deficiency associated liver disease (AATD).
Explore related
Medical disclaimer. This page summarizes public trial data for NCT03946449 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.